Physical performance, toxicity, and quality of life as assessed by the physician and the patient

被引:14
作者
Luoma, ML
Hakamies-Blomqvist, L
Sjöström, J
Mouridsen, H
Pluzanska, A
Malmstrom, P
Bengtsson, NO
Hultborn, R
Ostenstaad, B
Mjaaland, I
Valvere, V
Wist, E
Baldursson, G
Ahlgren, J
Blomqvist, C
机构
[1] Univ Helsinki, Dept Psychol, Appl Psychol Div, FI-00014 Helsinki, Finland
[2] Univ Uppsala Hosp, Dept Oncol, Uppsala, Sweden
[3] Med Ctr Hosp, Dept Oncol, Orebro, Sweden
[4] Univ Hosp Iceland, Dept Oncol, Reykjavik, Iceland
[5] Tromso Reg Hosp, Dept Oncol, Tromso, Norway
[6] Estonian Canc Ctr, Tallinn, Estonia
[7] Cent Hosp Rogaland, Stavanger, Norway
[8] Ulleval Hosp, Oslo, Norway
[9] Sahlgenska Sjukhuset, Gothenburg, Sweden
[10] Univ Umea Hosp, S-90185 Umea, Sweden
[11] Univ Lund Hosp, S-22185 Lund, Sweden
[12] Med Univ Lodz, Dept Oncol, Lodz, Poland
[13] Univ Copenhagen Hosp, Rigshosp, DK-2100 Copenhagen, Denmark
[14] Univ Helsinki, Cent Hosp, Helsinki, Finland
[15] Univ Helsinki, Swedish Sch Social Sci, Helsinki, Finland
关键词
D O I
10.1080/028418602317314055
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study was to study the relationship between physician-assessed quality of life parameters, i.e., toxicity and physical performance, and patients' self-reports of their quality of life (QoL). QoL was assessed at baseline and before each treatment. using the EORTC QLQ-C30. The WHO performance score (PS) and toxicity were assessed in physician interviews. The correlations between the WHO PS and the QLQ-C30 functioning scale scores varied from weak to moderate, depending on the scale. Strongest associations were found in physical-, social-, and role functioning, and in the global QoL. The QLQ-C30 nausea vomiting and diarrhea scales correlated moderately to corresponding WHO scores. A multiple linear regression analysis was used to analyze the contribution of WHO PS and toxicity variables to the global QoL. The best model explained only 16% of the variance of the global QoL score. The present findings highlight the importance of independent QoL assessments focused on those aspects of QoL not captured in clinical interviews with the physician.
引用
收藏
页码:44 / 49
页数:6
相关论文
共 24 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]   Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer [J].
Chan, S ;
Friedrichs, K ;
Noel, D ;
Pintér, T ;
Van Belle, S ;
Vorobiof, D ;
Duarte, R ;
Gil, MG ;
Bodrogi, I ;
Murray, E ;
Yelle, L ;
von Minckwitz, G ;
Korec, S ;
Simmonds, P ;
Buzzi, F ;
Mancha, RG ;
Richardson, G ;
Walpole, E ;
Ronzoni, M ;
Murawsky, M ;
Alakl, M ;
Riva, A ;
Crown, J .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2341-2354
[3]   Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer [J].
Doyle, C ;
Crump, M ;
Pintilie, M ;
Oza, AM .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) :1266-1274
[4]  
Fayers P, 1998, EORTC QLQ-C30 reference values
[5]  
Fayers P, 1995, EORTC QLQC 30 SCORIN
[6]   Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens [J].
Fossella, FV ;
DeVore, R ;
Kerr, RN ;
Crawford, J ;
Natale, RR ;
Dunphy, F ;
Kalman, L ;
Miller, V ;
Lee, JS ;
Moore, M ;
Gandara, D ;
Karp, D ;
Vokes, E ;
Kris, M ;
Kim, Y ;
Gamza, F ;
Hammershaimb, L .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) :2354-2362
[7]   Palliative effect of chemotherapy: Objective tumor response is associated with symptom improvement in patients with metastatic breast cancer [J].
Geels, P ;
Eisenhauer, E ;
Bezjak, A ;
Zee, B ;
Day, A .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) :2395-2405
[8]   Assessment of quality of life during chemotherapy [J].
Gunnars, B ;
Nygren, P ;
Glimelius, B .
ACTA ONCOLOGICA, 2001, 40 (2-3) :175-184
[9]   Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil.: A multicentre randomised phase III trial by the Scandinavian Breast Group [J].
Hakamies-Blomqvist, L ;
Luoma, ML ;
Sjöström, J ;
Pluzanska, A ;
Sjödin, M ;
Mouridsen, H ;
Ostenstad, B ;
Mjaaland, I ;
Ottosson-Lönn, S ;
Bergh, J ;
Malmström, PO ;
Blomqvist, C .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (11) :1411-1417
[10]   Timing of quality of life (QoL) assessments as a source of error in oncological trials [J].
Hakamies-Blomqvist, L ;
Luoma, ML ;
Sjöström, J ;
Pluzanska, A ;
Sjödin, M ;
Mouridsen, H ;
Ostenstad, B ;
Mjaaland, I ;
Ottosson, S ;
Bergh, J ;
Malmström, PO ;
Blomqvist, C .
JOURNAL OF ADVANCED NURSING, 2001, 35 (05) :709-716